164 related articles for article (PubMed ID: 32161312)
1. Co-inhibition of BET proteins and PI3Kα triggers mitochondrial apoptosis in rhabdomyosarcoma cells.
Boedicker C; Hussong M; Grimm C; Dolgikh N; Meister MT; Enßle JC; Wanior M; Knapp S; Schweiger MR; Fulda S
Oncogene; 2020 May; 39(19):3837-3852. PubMed ID: 32161312
[TBL] [Abstract][Full Text] [Related]
2. Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells.
Enßle JC; Boedicker C; Wanior M; Vogler M; Knapp S; Fulda S
Cancer Lett; 2018 Aug; 428():160-172. PubMed ID: 29709701
[TBL] [Abstract][Full Text] [Related]
3. The novel dual BET/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells.
Laszig S; Boedicker C; Weiser T; Knapp S; Fulda S
Cancer Lett; 2020 Aug; 486():46-57. PubMed ID: 32445837
[TBL] [Abstract][Full Text] [Related]
4. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
Haydn T; Metzger E; Schuele R; Fulda S
Cell Death Dis; 2017 Jun; 8(6):e2879. PubMed ID: 28617441
[TBL] [Abstract][Full Text] [Related]
5. Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells.
Erdogdu U; Dolgikh N; Laszig S; Särchen V; Meister MT; Wanior M; Knapp S; Boedicker C
Neoplasia; 2022 Feb; 24(2):109-119. PubMed ID: 34959030
[TBL] [Abstract][Full Text] [Related]
6. Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma.
Heinicke U; Kupka J; Fichter I; Fulda S
Oncogene; 2016 Jul; 35(28):3729-41. PubMed ID: 26616861
[TBL] [Abstract][Full Text] [Related]
7. JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis.
Heinicke U; Kupka J; Fulda S
Oncotarget; 2015 Nov; 6(35):37836-51. PubMed ID: 26473375
[TBL] [Abstract][Full Text] [Related]
8.
Dolgikh N; Hugle M; Vogler M; Fulda S
Cancer Res; 2018 Apr; 78(8):2000-2013. PubMed ID: 29437705
[TBL] [Abstract][Full Text] [Related]
9. BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.
Hogg SJ; Newbold A; Vervoort SJ; Cluse LA; Martin BP; Gregory GP; Lefebure M; Vidacs E; Tothill RW; Bradner JE; Shortt J; Johnstone RW
Mol Cancer Ther; 2016 Sep; 15(9):2030-41. PubMed ID: 27406984
[TBL] [Abstract][Full Text] [Related]
10. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.
Heinicke U; Fulda S
Cancer Lett; 2014 Aug; 351(1):50-8. PubMed ID: 24814395
[TBL] [Abstract][Full Text] [Related]
11. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide induces Noxa-dependent apoptosis in rhabdomyosarcoma cells and synergizes with antimicrotubule drugs.
Meister MT; Boedicker C; Graab U; Hugle M; Hahn H; Klingebiel T; Fulda S
Cancer Lett; 2016 Oct; 381(2):287-95. PubMed ID: 27521572
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
14. BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis.
Heinicke U; Haydn T; Kehr S; Vogler M; Fulda S
Oncogene; 2018 Sep; 37(39):5325-5339. PubMed ID: 29858601
[TBL] [Abstract][Full Text] [Related]
15. BCL-x
Faqar-Uz-Zaman SF; Heinicke U; Meister MT; Vogler M; Fulda S
Cancer Lett; 2018 Jan; 412():131-142. PubMed ID: 28947136
[TBL] [Abstract][Full Text] [Related]
16. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
[TBL] [Abstract][Full Text] [Related]
17. A direct comparison of selective BH3-mimetics reveals BCL-X
Bierbrauer A; Jacob M; Vogler M; Fulda S
Br J Cancer; 2020 May; 122(10):1544-1551. PubMed ID: 32203216
[TBL] [Abstract][Full Text] [Related]
18. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
[TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells.
Zhang XD; Gillespie SK; Borrow JM; Hersey P
Mol Cancer Ther; 2004 Apr; 3(4):425-35. PubMed ID: 15078986
[TBL] [Abstract][Full Text] [Related]
20. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling.
Zhang HT; Gui T; Sang Y; Yang J; Li YH; Liang GH; Li T; He QY; Zha ZG
J Cell Biochem; 2017 Aug; 118(8):2182-2192. PubMed ID: 28059436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
